Skip to main content
. 2008 Sep 30;113(8):1619–1630. doi: 10.1182/blood-2008-03-144790

Figure 7.

Figure 7

Activity of imatinib mesylate and the second generation tyrosine kinase inhibitors nilotinib and dasatinib against a selection of BCR-ABL1 mutants found in patients with CML. All concentrations are shown in nanomoles per milliliter and represent IC50 values.